Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 6Lung Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Motor Activity 3Hodgkin Disease 2Hematopoietic and Lymphoid System Neoplasm 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Stress Disorders, Post-Traumatic 1Sleep Wake Disorders 1Sedentary Behavior 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pathologically Proven Gastrointestinal Malignancy 1Obesity 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Insulin Resistance 1Inflammatory Breast Neoplasms 1Hematopoietic and Lymphatic System Neoplasm 1

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Exercise Test × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡